About GLP1 Base

Millions of people now take GLP-1 medicines, and millions more see peptides like BPC-157 promoted online. The facts are scattered across trial papers, product labels and regulator notices that change month to month, in different countries. GLP1 Base puts them in one place and explains them simply.

What we do

• Explain each molecule in plain English and in expert detail, including what it does inside the body.
• Show how strong the evidence really is, from animal studies to approved medicines.
• Track what regulators in each country allow, with a dated source for every entry.
• Record the companies, prices, lawsuits and politics that shape the market.

What we do not do

• We do not give medical advice, dosing or mixing instructions.
• We do not sell, source or link to sellers of any substance.
• We do not take money from drugmakers, telehealth providers or peptide sellers.

Who is behind it

GLP1 Base is published by Mitsi and powered by KeenShift. It is funded by our own iOS apps and by Pro services for businesses, never by the companies we write about. Pages about approved GLP-1 medicines may show one of our apps, always labelled "Our app"; the apps do not change what we publish. Contact: mitsi@keenshift.ai.

Read how we verify every fact.